ContributorsPublishersAdvertisers

Oncology Overview: Isatuximab-irfc (Sarclisa) for Relapsed/Refractory Multiple Myeloma

pharmacytimes.com
 2021-10-05

Cover picture for the articleIsatuximab-irfc (Sarclisa; sanofi-aventis) provides patients with another option for treatment and significantly reduces the risk of disease progression or death. Isatuximab-irfc (Sarclisa; sanofi-aventis US LLC) is a targeted monoclonal antibody approved for patients with relapsed and refractory multiple myeloma—the second most common blood cancer.1,2. More than 130,000 Americans are...

www.pharmacytimes.com

Comments / 0

Comments / 0